Agenus Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 5, 2024 to Discuss Your Rights – AGEN

Core Viewpoint - The Gross Law Firm is notifying shareholders of Agenus Inc. regarding a class action lawsuit due to alleged misleading statements about the effectiveness of their immuno-oncology products [1][2]. Group 1: Allegations - The complaint claims that during the class period from January 23, 2023, to July 17, 2024, the defendants made materially false and misleading statements about the combination therapy of botensilimab and balstilimab [2]. - It is alleged that the effectiveness of the combination therapy was overstated, leading to inflated clinical results and regulatory and commercial prospects [2]. - As a result, the company's public statements were deemed materially false and misleading throughout the relevant period [2]. Group 2: Class Action Details - Shareholders who purchased shares of Agenus during the specified class period are encouraged to register for the class action, with a deadline set for November 5, 2024 [2]. - Registration allows shareholders to receive updates on the case through portfolio monitoring software [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].